#196
|
|||
|
|||
îçíà÷àåò "êëè÷åñêè âàæíîå èçìåðèìîå/ïîääàþùååñÿ èçìåðåíèþ"
|
#197
|
|||
|
|||
|
#198
|
|||
|
|||
Äëÿ ïðèâëå÷åíèÿ èíòåðåñà ê ðàçäåëó, áóäó ïîäáðàñûâàòü ñþäà àôîðèçìû è öèòàòû...
“When doctors, statisticians and scientists become ill, they ask "Who is the best doctor for this problem?" and not "Which multi-centre controlled trial would be best for me?" (--E.J. Freireich from the MD Anderson Hospital). “Any study that reports a certain number of consecutive cases without a complication (death) actually means that number of cases plus two were performed with two complications (deaths) ;the first and last.” (--Michael Hoffman). |
#199
|
|||
|
|||
Äîáðûé âå÷åð, Àëåêñàíäð.
Êàê çâó÷èò ïðåäëîæåíèå öåëèêîì? Measurable èìååò åùå çíà÷åíèå "óìåðåííûé; çàìåòíûé" Àíãë-àíãë ñëîâàðü Collins äàåò ñëåäóþùóþ òðàêòîâêó ýòîìó ñëîâó: able to be measured; perceptible or significant |
#200
|
|||
|
|||
Äà, ñîáñòâåííî, ÿ åãî öåëèêîì è ïðèâåë, âîò òåêñò:
relative contraindications include recent central nervous system bleeds; intracranial or spinal lesions at high risk for bleeding; active bleeding (morethan two units transfused in 24 h); chronic, clinically significant measurable bleeding (>48 h); thrombocytopenia (<50 000/mm3); |
#201
|
|||
|
|||
Ëàáîðàòîðíî ãåìîãëîáèí, ãåìàòîêðèò è ò.ä.
×åñòíî ãîâîðÿ, íå ïîíèìàþ, ÷òî àâòîðû ïîäðàçóìåâàëè ïîä "êëèíè÷åñêè âàæíîå èçìåðèìîå êðîâîòå÷åíèå", ïðèçíàêè øîêà èëè ÄÂÑ-ñèíäðîìà, èëè ÷òî òî äðóãîå... |
#202
|
|||
|
|||
À åñëè äâèãàòüñÿ îò ñòàíäàðòíîé îøèáêè ïåðåâîä÷èêîâ,
significant - äîñòîâåðíûé, à íå çíà÷èòåëüíûé? ÇÛ Ñïàñèáî çà èíòåðåñ ê âîïðîñó. |
#203
|
|||
|
|||
Ïîêà æäåì "òÿæåëîé àðòèëëåðèè" ïî èçìåðåíèþ õðîíè÷åñêîãî êðîâîòå÷åíèÿ, åù¸ îäèí ãåìàòîëîãè÷åñêè îðèåíòèðîâàíûé êâèç :-)
to discuss major areas of concern, identify the therapeutic issues and develop recommendations and review-associated evidence for the management of myeloma bone disease. Íó è äëÿ "ïîäíÿòèÿ" ïîñòà.... “Any study that reports a certain number of consecutive cases without a complication (death) actually means that number of cases plus two were performed with two complications (deaths) ;the first and last.” (--Michael Hoffman) “The good thing about standard of care is that there are so many to choose from.” |
#204
|
|||
|
|||
Âñå åù¸ æäó ïîäñêàçîê ïî "èçìåðèìîìó õðîíè÷åñêîìó êðîâîòå÷åíèþ (48 ÷àñ.)" è
review-associated evidence |
#205
|
|||
|
|||
ß áû ïåðåâîäèë ñëåäóþùèì îáðàçîì:
chronic, clinically significant measurable bleeding (>48 h); õðîíè÷åñêîå (ïðîäîëæàþùååñÿ ñâûøå 48 ÷àñîâ) êëèíè÷åñêè çíà÷èìîå êðîâîòå÷åíèå, îïðåäåëÿåìîå âèçóàëüíî è/èëè ëàáîðàòîðíî to discuss major areas of concern, identify the therapeutic issues and develop recommendations and review-associated evidence for the management of ...[ñ öåëüþ] îáñóäèòü îñíîâíûå íåðåøåííûå ïðîáëåìû, îïðåäåëèòü òåðàïåâòè÷åñêèå ïîäõîäû è ðàçðàáîòàòü ðåêîìåíäàöèè ñ âûäåëåíèåì ãðàäàöèé [ñèëû] ðåêîìåíäàöèé íà îñíîâå [ïðîâåäåííîãî] ñèñòåìàòè÷åñêîãî îáçîðà äëÿ ëå÷åíèÿ... Íî ýòî òîëüêî ìîå ÈÌÕÎ . |
#206
|
|||
|
|||
-ñàêòîñàëüïèíêñ
-íàäâëàãàëèùíàÿ àìïóòàöèÿ ìàòêè ñ ïðèäàòêàìè íèêàê íå ìîãó íàéòè íîðìàëüíîãî ïåðåâîäà, ÷òîáû õîòü ÷òî-òî íàøëîñü â ïàáìåäå |
#207
|
|||
|
|||
supracervical hysterectomy
È íå èìååò çíà÷åíèÿ ñ ïðèäàòêàìè èëè áåç. Èõ ïèøèòå îòäåëüíî (äðóãîé îðãàí). À "ñàêòîñàëüïèíêñ", íå óâåðåí, ÷òî â àíãëèéñêîì åñòü àíàëîãè÷íûé òåðìèí. ×åì Âàñ íå óñòðàèâàåò chronical salpyngitis with obstruction |
#208
|
||||
|
||||
Äîðîãèå êîëëåãè, ïîäñêàæèòå ïîæàëóéñòà ïåðåâîä äëÿ lifetime analytic horizon è quality-adjusted life years
Âðîäå ïåðåâåëà êàê "ïîæèçíåííûé àíàëèòè÷åñêèé ãîðèçîíò" è "ãîäû æèçíè ñ ïîïðàâêîé íà êà÷åñòâî æèçíè", íî çàñîìíåâàëàñü - âîçìîæíî, åñòü äðóãîé îáùåïðèíÿòûé âàðèàíò?
__________________
Àííà, âðà÷-ýíäîêðèíîëîã Âîðîíåæ, êëèíèêà Íåïëàöåáî |
#209
|
|||
|
|||
|
#210
|
|||
|
|||
Horison ïåðåâîäèòñÿ è êàê "ïðîìåæóòîê (âðåìåíè)" òîáòî (óêð :-) - "àíàëèçèðóåòñÿ íà ïðîòÿæåíèè âñåé æèçíè".
Íó, ìíå òàê êàæåòñÿ (ñ) quality-adjusted life years îäíîçíà÷íîãî ïåðåâîäà íå âñòðå÷àë, áûëî è "êîëè÷åñòâî ëåò æèçíè ñ ñîõðàíåííûì/ïðèåìëåìûì êà÷åñòâîì" À âîò èç ìóëüòèòðàíà quality adjusted life year ìåä. ãîä æèçíè ñ ïîïðàâêîé íà å¸ êà÷åñòâî (Dimpassy) Quality adjusted life year ìåä. ãîä æèçíè, ïðîæèòûé êà÷åñòâåííî (ñîêð. QALY alf77); ïðèâåä¸ííûé ïåðåñ÷èòàííûé ïî êà÷åñòâó ãîä æèçíè (alf77); ñêîððåêòèðîâàííûé íà êà÷åñòâî æèçíè ãîä (alf77); ñîõðàí¸ííûé ãîä æèçíè ñ ó÷¸òîì å¸ êà÷åñòâà (Vosoni) |